Table 1.
Patient and treatment characteristics.
| Characteristic | N | % |
|---|---|---|
| Age (years, median [range]) | 21 (2–74) | |
| < 20 years (pediatric) | 40 | 48.2 |
| ≥ 20 years (adult) | 43 | 51.8 |
| Histology–Pediatric | ||
| Germ cell tumor | 15 | 37.5 |
| Medulloblastoma | 14 | 35 |
| Miscellaneous | 11 | 27.5 |
| Histology–Adult | ||
| Glioblastoma | 10 | 23.3 |
| Leptomeningeal carcinomatosis | 7 | 16.3 |
| Germ cell tumor | 4 | 9.3 |
| Miscellaneous | 22 | 51.2 |
| Sex | ||
| Male | 54 | 55.6 |
| Female | 29 | 44.4 |
| Height (cm, median [range]) | 165 (88–192) | |
| Body-mass index (kg/m2, median [range]) | 20.4 (10.9–28.4) | |
| Weight loss grade ≥ 1* | 13 | 15.7 |
| Nausea grade ≥ 2* | 20 | 24.1 |
| Total CSI dose (Gy, median [range]) | 36.0 (12.0–45.0) | |
| Total CSI fraction number (fractions, median [range]) | 20 (8–30) | |
| Fractional CSI dose (Gy, median [range]) | 1.5 (1.2–3.0) | |
| CSI field | ||
| Brain-Sacrum | 76 | 91.6 |
| Posterior fossa-Sacrum | 2 | 2.4 |
| C1 spine-Sacrum | 5 | 6.0 |
| Beam on time (seconds, median [range]) | 538.1 (310.6–964.8) | |
| Sedation during treatment | 7 | 8.4 |
| Concurrent chemotherapy | 29 | 34.9 |
| Overall CSI treatment time (days, median [range]) | 32 (11–108) | |
| Medically-indicated treatment interruptions | 28 | 33.7 |
| Days (median [range]) | 5 (1–58) | |
| Adaptive during CSI | 3 | 3.6 |
CSI craniospinal irradiation; Gy gray.
*Based on common terminology criteria for adverse events version 5.0.